Founders Grove Wealth Partners’s Pfizer PFE Stock Holding History

Founders Grove Wealth Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,493	Closed	-$238K	–	190
2026 Q1	$238K	Buy	+8,493	New	+$226K	0.05%	147

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Founders Grove Wealth Partners's PFE Position: Q2 2026 in Review

Founders Grove Wealth Partners sold out of Pfizer (PFE) in Q2 2026, closing a stake of 8,493 shares — an estimated $238K sold.

Founders Grove Wealth Partners first reported a position in PFE in Q1 2026 and held it in 1 quarter. The position peaked at $238K in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Founders Grove Wealth Partners reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Founders Grove Wealth Partners sold 8,493 Pfizer shares in Q2 2026, an estimated $238K.
Founders Grove Wealth Partners first reported a position in Pfizer in Q1 2026 and held it in 1 quarter.
Founders Grove Wealth Partners's Pfizer position peaked at $238K in Q1 2026.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Founders Grove Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.